Takara has patented a method for efficiently proliferating stem cells using a novel recombinant fibronectin fragment. The patent covers a specific recombinant polypeptide with defined amino acid sequences that maintain the undifferentiated state of stem cells. GlobalData’s report on Takara gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Takara Holdings Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Takara, Anti-viral antigen-based compositions was a key innovation area identified from patents. Takara's grant share as of May 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant fibronectin fragment for efficient stem cell proliferation

Source: United States Patent and Trademark Office (USPTO). Credit: Takara Holdings Inc

A recently granted patent (Publication Number: US11999972B2) discloses a novel recombinant polypeptide designed to maintain the undifferentiated state of stem cells. The polypeptide comprises specific repeats of human fibronectin III sequences, with variants allowed as long as they maintain at least 90% identity to the original sequences. The molecular weight of the recombinant polypeptide is limited to 100 kDa or less, ensuring its effectiveness in stem cell maintenance. Additionally, the patent includes claims for variations of the polypeptide, such as different combinations of fibronectin III repeats, expanding the potential applications of this innovative molecule.

Furthermore, the patent covers the use of the recombinant polypeptide in various solid phases, including devices for cell culture and carriers coated with the polypeptide. These solid phases can range from dishes and plates to beads and membranes, providing a versatile platform for stem cell research and applications. By specifying the types of solid phases that can be coated with the recombinant polypeptide, the patent aims to facilitate the integration of this novel molecule into existing cell culture technologies, potentially advancing the field of regenerative medicine and biotechnology.

To know more about GlobalData’s detailed insights on Takara, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies